Concepedia

Quantitative <sup>68</sup>Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following <sup>177</sup>Lu-PSMA-617 (VISION Trial)

Phillip H. Kuo, Michael J. Morris, Jacob Hesterman, A. Tuba Kendi, Kambiz Rahbar, Xiao X. Wei, Bruno Fang, Nabil Adra, Rohan Garje, Jeff M. Michalski,

Radiology · 2024 · 91 citations · 24 references

DOIFull text

Open access

Concepts

Abstract

Visual 68 Ga-PSMA-11 PET/CT eligibility criteria helped identify participants with metastatic castration-resistant prostate cancer who benefitted from 177 Lu-PSMA-617 therapy in the VISION trial, with higher 68 Ga-PSMA-11 uptake associated with improved outcomes.

References

24

Regression Models and Life-Tables

D. R. Cox · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1972 · 39.3K citations · Full text

, , +16

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor, Johann S. de Bono, Kim N. et al. · New England Journal of Medicine · 2021 · 2.6K citations · Full text

, , +17

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0

Wolfgang P. Fendler, Matthias Eiber, Mohsen Beheshti et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 755 citations

, , +17

An application of changepoint methods in studying the effect of age on survival in breast cancer

Cécile Parent Contal, John O’Quigley · Computational Statistics & Data Analysis · 1999 · 589 citations

, , +10

Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.

Ron Israeli, C. Thomas Powell, William R. Fair et al. · PubMed · 1993 · 532 citations

, , +14